Neutropenia: state of the knowledge part I

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Neutrophil physiology and the critical role of neutrophils in immune defense.
• Chemotherapy-induced neutropenia (CIN) as a significant dose-limiting toxicity in cancer therapy.
• The profound impact of CIN on patient outcomes, treatment efficacy, and healthcare costs.

Purpose of the Study:

• To comprehensively review neutrophil physiology and the multifaceted consequences of chemotherapy-induced neutropenia (CIN).
• To examine existing CIN risk assessment models and national practice guidelines.
• To elucidate the knowns and unknowns surrounding CIN, including its impact on febrile neutropenia and infection.

Main Methods:

• Extensive literature review encompassing published neutropenia research, clinical guidelines, and meta-analyses.
• Inclusion of data from NIH and Oncology Nursing Society funded studies.
• Synthesis of information presented at expert panel symposiums.

Main Results:

• Compilation of current literature on CIN risk assessment, management strategies, and practice guidelines.
• Analysis of CIN's impact on dose-dense/dose-intense cancer regimens, associated complications, and hospitalization costs.
• Identification of established and emerging treatment strategies for CIN.

Conclusions:

• CIN is the most frequent dose-limiting toxicity in cancer therapy, necessitating robust management protocols.
• Development of practice guidelines and risk models aids in pre-chemotherapy assessment and management of febrile neutropenia.
• CIN presents a global challenge impacting patients, families, practitioners, and healthcare systems, with ongoing research needed.